Lab guide · Tissue & thymic peptides
What Is BPC-157? Pentadecapeptide Peptide Research Overview
What is BPC-157? It is a synthetic 15-amino-acid peptide described as part of a protein found in gastric juice, studied almost entirely in cell and rodent models. This guide covers its structure, the pathways reported in published work, what the evidence does and does not show, and how it is handled in the lab.
Key takeaways
- BPC-157 is a synthetic pentadecapeptide, GEPPPGKPADDAGLV, with formula C62H98N16O22 and a mass of about 1419.5 g/mol.
- It is described as a partial sequence of a gastric-juice protein, and most studies come from rat and cell models.
- Cell studies report VEGFR2–Akt–eNOS signalling, but no dedicated receptor has been established.
- A 2025 systematic review found 35 preclinical studies, one small clinical report and no human safety data.
What is BPC-157?
So, what is BPC-157? BPC-157 (Body Protection Compound-157) is a synthetic peptide of 15 amino acids. It is described as a partial sequence of a protein found in gastric juice, and the literature also uses the names PL 14736, bepecin, PLD-116 and PCO-02 (Vasireddi et al., 2025). It has been studied mainly in rodent injury models, alongside cell studies of blood-vessel and fibroblast biology.
A 2025 systematic review in the HSS Journal screened 544 articles published between 1993 and 2024 and included 36 studies: 35 preclinical and one clinical. That ratio is the most important context for everything below.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (GEPPPGKPADDAGLV) |
| Length | 15 amino acids (pentadecapeptide) |
| Molecular formula | C62H98N16O22 |
| Molecular weight | ≈1419.5 g/mol (average); 1418.704 Da monoisotopic, calculated from the formula |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Class | Synthetic linear peptide; gastric protein fragment |
The formula, mass and CAS number match the PubChem record. The sequence contains four prolines, three acidic residues (one Glu, two Asp) and a single lysine, and it has no cysteine, methionine or tryptophan. That composition means there are no disulfide bonds to form and no obvious oxidation-prone side chains. The CAS number refers to the free peptide, and salt forms can be registered separately, so a batch report should state exactly which form was tested.
Discovery and research history
The systematic review dates the first description of BPC-157 to 1992, and its literature search found studies from 1993 onwards. Predrag Sikirić and colleagues introduced it as a peptide from gastric juice with cytoprotective effects, and the early work focused on gastric and intestinal lesions in rats.
Research later widened to tendon, ligament, muscle and bone healing, vascular biology and some neurological models. Several of the musculoskeletal papers share authors (Sikirić, Staresinic, Krivic, Brcic and Seiwerth), but other groups have published too. Examples are Hsieh et al. (2017) and Hsieh et al. (2020) on endothelial signalling, plus the Chang et al. tendon-fibroblast studies of 2011 and 2014 summarised in the review. Independent replication is therefore partial rather than absent.
Proposed mechanisms and pathways
Angiogenic and nitric-oxide signalling
The best-characterised cell findings concern endothelial cells. In Hsieh et al. (2017, J Mol Med), BPC-157 promoted angiogenesis in the chick chorioallantoic membrane (CAM) assay and in a tube-formation assay. It increased VEGFR2 expression and internalisation and activated VEGFR2–Akt–eNOS signalling in a time-dependent way, and the effect was suppressed by the endocytosis inhibitor dynasore.
A follow-up in Scientific Reports (2020) reported that eNOS activation involved VEGFR2 activation and endocytosis, Akt activation and reduced interaction between caveolin-1 and eNOS.
Fibroblast, growth and inflammatory pathways
The systematic review also summarises reports of increased FAK and paxillin expression in cultured tendon fibroblasts, raised growth hormone receptor expression in those cells, ERK1/2 phosphorylation, and lower COX-2, IL-6 and TNF-α in some models. Rat studies additionally report altered serotonin and dopamine signalling.
Mechanism status. None of the sources used here establishes a single dedicated BPC-157 receptor. The pathways above are measured associations, not a confirmed mechanism of action.
Main research areas
- Musculoskeletal models: transected or crushed rat tendon, ligament and muscle, and a rabbit non-union model, assessed by histology, biomechanics and function.
- Gastrointestinal models: gastric and intestinal lesions and colitis in rodents, the original focus of the work.
- Vascular biology: endothelial migration, tube formation, VEGFR2 and nitric-oxide signalling.
- Neuroscience models: dopamine and serotonin pathways and toxin-induced brain injury in rats.
What published studies actually show
Evidence quality matters more than volume here. The table separates what is established from what is reported in each model type, using the 2025 systematic review and the primary papers cited above.
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula, mass and CAS number are verifiable in PubChem. |
| Cell studies | Endothelial VEGFR2–Akt–eNOS signalling and tube formation; tendon fibroblast outgrowth, migration and survival. |
| Animal studies | Improved structural, biomechanical and functional measures in rat tendon, muscle and ligament injury models; no acute toxicity under 6 weeks in rats and dogs. |
| Human research | One retrospective report of 12 patients with subjective outcomes; no human safety data; a phase I registration of unknown status. |
| Unconfirmed | A single receptor, a unifying mechanism and any clinical effect. |
A useful way to read any BPC-157 paper:
- Identify the model. Cultured cells, rodents and humans answer different questions.
- Check independence. Note whether the authors overlap with earlier papers.
- Look at the outcome measure. Histology and biomechanics are objective; subjective reports are not.
- Check the material. Was the peptide identity and purity documented?
Scientific limitations and open questions
- Nearly all evidence is preclinical: 35 of the 36 studies in the 2025 review.
- Several animal papers share authors, and independent replication is limited.
- No dedicated receptor is established, and reported pathways are interconnected.
- Animal safety work did not extend beyond 6 weeks, and no human safety data were found.
- Study heterogeneity prevented a quantitative meta-analysis.
- Regulatory status can change; the review lists an FDA Category 2 designation (2023) and a specific WADA prohibition (2022).
- Unregulated products carry contamination and identity risks, which is why analytical documentation matters.
Analytical and laboratory considerations
Identity is confirmed by HPLC for purity and mass spectrometry for mass. The expected monoisotopic mass is 1418.704 Da, so the [M+H]+ ion appears near m/z 1419.71 (calculated). Mass spectrometry methods have also been used to detect BPC-157 metabolites in urine for anti-doping work, as summarised in the review.
Because the sequence has no Cys, Met or Trp residues, it is less oxidation-prone than many peptides, but standard handling still applies: cold, dry, sealed and protected from light. See how to store peptides and the guide to reading a peptide COA. Baltic Peptides publishes batch reports on its COA page, and current formats are on the BPC-157 product page.
Sources and further reading
- Vasireddi N. et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 21(4):485-495. PubMed · PMC full text
- Hsieh M.J. et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 95:323-333. PubMed
- Hsieh M.J. et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep 10:17078. PMC full text
- PubChem compound record for BPC-157 (CID 9941957). PubChem
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is BPC-157?
What is the amino acid sequence of BPC-157?
What is the molecular weight and CAS number of BPC-157?
Who discovered BPC-157 and when?
Is BPC-157 the same as TB-500?
Is there human clinical evidence for BPC-157?
Is BPC-157 approved as a medicine?
What does a BPC-157 certificate of analysis show?
Keep reading
Related reading
BPC-157
Current batches, formats and the COA for BPC-157.
What is TB-500?
How thymosin beta-4 research differs from BPC-157 studies.
Peptide blends explained
Why component research does not define a combined formulation.
Research-grade BPC-157, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
